A GOP U.S. Senator who has been active on 340B matters for decades last week asked President Biden’s pick to be the U.S. Health and Human Services Department’s top lawyer if HHS could be doing more to protect the 340B
…
Articles by : Tom Mirga, Editor at Large
Efforts to pass federal drug pricing legislation, pronounced dead by many last week, arose in time for Halloween.
Liberal and conservative congressional Democrats and the White House reportedly are still trying to strike a deal centered on letting Medicare negotiate
…
The Biden administration last Friday, as widely expected, proposed withdrawing or repealing a Trump administration final rule that will automatically extinguish all U.S. Health and Human Services (HHS) regulations if HHS does not renew each regulation within a certain timeframe.
…
A federal district judge in Indianapolis late this afternoon set aside and vacated the federal government’s May 17 finding that drug manufacturer Eli Lilly’s denials of 340B ceiling prices when covered entities use contract pharmacies violate the 340B statute.
A
…
2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.
Attention on health care lobbying in Washington today focuses on the huge sums the drug industry is spending fighting Democratic drug price
…
Drug manufacturer Astra Zeneca and the federal government both want a federal district judge in Delaware to rule quickly in the drug company’s lawsuit over the government’s 340B contract pharmacy requirements.
The two sides, however, are miles apart on why
…
U.S. District Judge Dabney Friedrich of the District of Columbia has been assigned to a fourth 340B contract pharmacy lawsuit.
Boehringer Ingelheim’s (BI) lawsuit in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies
…
A federal court ruling on the legality and constitutionality of Arkansas’s 340B nondiscrimination law might not come until sometime in 2023.
U.S. Senior District Judge Billy Roy Wilson on Monday issued an initial scheduling order in the drug industry lawsuit
…
The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.
HRSA updated its fiscal year 2021 audit results on its website last week.
The federal government and the two groups that sued it separately to force it to issue long delayed 340B administrative dispute resolution (ADR) regulations agreed last night to keep stays in place in both lawsuits until Jan. 3, 2022. Meanwhile,
…